Association between clinical outcome and gene mutation in children with Fanconi anemia

CHANG Li-Xian, REN Ruan-Ruan, YANG Wen-Yu, ZHANG Jia-Yuan, WAN Yang, LIU Tian-Feng, ZHANG Li, CHEN Xiao-Juan, ZHU Shuai, RUAN Min, CHEN Xia, LIU Xiao-Ming, QI Ben-Quan, ZHANG Ran-Ran, ZOU Yao, CHEN Yu-Mei, ZHU Xiao-Fan

Chinese Journal of Contemporary Pediatrics ›› 2016, Vol. 18 ›› Issue (8) : 742-745.

PDF(1245 KB)
PDF(1245 KB)
Chinese Journal of Contemporary Pediatrics ›› 2016, Vol. 18 ›› Issue (8) : 742-745. DOI: 10.7499/j.issn.1008-8830.2016.08.014
CLINICAL RESEARCH

Association between clinical outcome and gene mutation in children with Fanconi anemia

  • CHANG Li-Xian, REN Ruan-Ruan, YANG Wen-Yu, ZHANG Jia-Yuan, WAN Yang, LIU Tian-Feng, ZHANG Li, CHEN Xiao-Juan, ZHU Shuai, RUAN Min, CHEN Xia, LIU Xiao-Ming, QI Ben-Quan, ZHANG Ran-Ran, ZOU Yao, CHEN Yu-Mei, ZHU Xiao-Fan
Author information +
History +

Abstract

Objective To investigate the association between clinical outcome and gene mutations in children with Fanconi anemia (FA). Methods A retrospective analysis was performed for the clinical data of six children with the same severity of FA and receiving the same treatment. At first, single cell gel electrophoresis and chromosome breakage induced by mitomycin C were performed for diagnosis. Then the gene detection kit for congenital bone marrow failure diseases or complementation test was used for genotyping of FA. Finally the association between the clinical outcome at 3, 6, 9, or 12 months after treatment and gene mutation was analyzed. Results Of all the six FA children, five had FANCA type disease, and one had FANCM type disease; four children carried two or more FA gene mutations. Among the children with the same severity of FA, those with more FA mutations had a younger age of onset and poorer response to medication, and tended to progress to a severe type. Conclusions Children carrying more than two FA mutations have a poor clinical outcome, and hematopoietic stem cell transplantation should be performed as soon as possible.

Key words

Fanconi anemia / Clinical outcome / Gene mutation / Child

Cite this article

Download Citations
CHANG Li-Xian, REN Ruan-Ruan, YANG Wen-Yu, ZHANG Jia-Yuan, WAN Yang, LIU Tian-Feng, ZHANG Li, CHEN Xiao-Juan, ZHU Shuai, RUAN Min, CHEN Xia, LIU Xiao-Ming, QI Ben-Quan, ZHANG Ran-Ran, ZOU Yao, CHEN Yu-Mei, ZHU Xiao-Fan. Association between clinical outcome and gene mutation in children with Fanconi anemia[J]. Chinese Journal of Contemporary Pediatrics. 2016, 18(8): 742-745 https://doi.org/10.7499/j.issn.1008-8830.2016.08.014

References

[1] D'Andrea AD,Grompe M.The Fanconi anaemia/BRCA pathway[J].Nat Rev Cancer,2003,3(1):23-34.
[2] Blanche P.Diagnostic Evaluation of FA[M]//Mary EE,Dave F,Lynn F,et al.Fanconi anemia:Guidelines for diagnosis and management[M].3rd ed.Eugene:Fanconi Anemia Research Fund Inc,2008:34-53.
[3] 张丽,刘强,邹尧,等.单细胞凝胶电泳试验在范可尼贫血诊断中的意义及其与丝裂霉素C试验相关性研究[J].中华儿科杂,2013,51(2):122-125.
[4] 齐军元,邵英起,刘永泽,等.单个细胞凝胶电泳分析在范可尼贫血诊断中的应用[J].中华血液学杂志,2006,27(10):690-693.
[5] International Atomic Energy Agency.Dicentric analysis[M]/Cytogenetic analysis for radiation dose assessment:a manual.Vienna:International Atomic Energy Agency,2001:27-59.
[6] Wang AT,Smogorzewska A.SnapShot:Fanconi anemia and associated proteins[J].Cell,2015,160(1-2):354-354.
[7] Alan D,D'Andrea MD.The Fanconi anemia and breast cancer susceptibility pathway[J].N Engl J Med,2010,362(20):1901-1919.
[8] Kutler DI,Singh B,Satagopan J,et al.A 20-year perspective on the international Fanconi anemia Registry (IFAR)[J].Blood 2003,101(4):1249-1256.
[9] Myers K,Davies SM,Harris RE,et al.The clinical phenotype of children with Fanconi anemia caused by biallelic FANCD1/BRCA2 mutations[J].Pediatr Blood Cancer,2012,58(3):462-465.
[10] Seal S,Thompson D,Renwick A,et al.Breast Cancer Susceptibility Collaboration (UK):Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles[J].Nat Genet,2006,38(11):1239-1241.
[11] Rahman N,Seal S,Thompson D,et al.Breast Cancer Susceptibility Collaboration (UK):PALB2,which encodes a BRCA2-interacting protein,is a breast cancer susceptibility gene[J].Nat Genet 2007,39(2):165-167.
[12] Reid S,Schindler D,Hanenberg H,et al.Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer[J].Nat Genet,2007,39(2):162-164.
[13] Wark L,Novak D,Sabbaghian N,et al.Heterozygous mutations in the PALB2 hereditary breast cancer predisposition gene impact on the three-dimensional nuclear organization of patient-derived cell lines[J].Genes Chromosomes Cancer,2013,52(5):480-494.
[14] Thompson ER,Doyle MA,Ryland GL,et al.Exome sequencing identifies rare deleterious mutations in DNA repair genes FANCC and BLM as potential breast cancer susceptibility alleles[J].PLoS Genet,2012,8(9):el002894.
[15] Levy-Lahad E,Friedman E.Cancer risks among BRCA1 and BRCA2 mutation carriers[J].Br J Cancer,2007,96(1):11-15.
[16] Smetsers S,Muter J,Bristow C,et al.Heterozygote FANCD2 mutations associated with childhood T cell ALL and testicular seminoma[J].Fam Cancer,2012,11(4):661-665.
[17] Koptyra M,Stoklosa T,Hoser G,et al.Monoubiquitinated Fanconi anemia D2(FANCD2-Ub) is required for BCR-ABL1 kinase-induced leukemogenesis[J].Leukemia,2011,25(8):1259-1267.
[18] Chang L,Yuan W,Zeng H,et al.Whole exome sequencing reveals concomitant mutations of multiple FA genes in individual Fanconi anemia patients[J].BMC Med Genomics,2014,7:24.
PDF(1245 KB)

Accesses

Citation

Detail

Sections
Recommended

/